[go: up one dir, main page]

PE20080338A1 - 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa) - Google Patents

4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)

Info

Publication number
PE20080338A1
PE20080338A1 PE2007000768A PE2007000768A PE20080338A1 PE 20080338 A1 PE20080338 A1 PE 20080338A1 PE 2007000768 A PE2007000768 A PE 2007000768A PE 2007000768 A PE2007000768 A PE 2007000768A PE 20080338 A1 PE20080338 A1 PE 20080338A1
Authority
PE
Peru
Prior art keywords
etansulfonil
isoquinolin
phenol
amino
akt
Prior art date
Application number
PE2007000768A
Other languages
English (en)
Inventor
Joseph Sajan
Renhua Li
Michael R Myers
Aktham Aburub
Jenny Pingqi Dai
Christopher Randall Schmid
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20080338A1 publication Critical patent/PE20080338A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE AL COMPUESTO 4-[5-(2-AMINO-ETANSULFONIL)-ISOQUINOLIN-7-IL]-FENOL EN LA FORMA DE DICLORHIDRATO O SEMI-HIDRATO MONOCLORHIDRATO. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA JUNTO A EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES, EN DONDE EL pH DE DICHA COMPOSICION, CUANDO SE DILUYE CON UN SOLVENTE ACUOSO, ES MENOS DE 4.2 Y MAYOR DE 2.0. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE MIELOMA MULTIPLE, CANCER DE PULMON DE CELULAS NO PEQUENAS, GLIOBLASTOMA, NEUROBLASTOMA, ENDOMETRIO, TIROIDES, ENTRE OTROS
PE2007000768A 2006-06-20 2007-06-18 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa) PE20080338A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80526006P 2006-06-20 2006-06-20
US88576507P 2007-01-19 2007-01-19

Publications (1)

Publication Number Publication Date
PE20080338A1 true PE20080338A1 (es) 2008-04-25

Family

ID=38834248

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000768A PE20080338A1 (es) 2006-06-20 2007-06-18 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)

Country Status (28)

Country Link
US (1) US7998977B2 (es)
EP (1) EP2035385B1 (es)
JP (1) JP2009541335A (es)
KR (1) KR101067551B1 (es)
AR (1) AR061240A1 (es)
AT (1) ATE455102T1 (es)
AU (1) AU2007261120A1 (es)
BR (1) BRPI0713136A2 (es)
CA (1) CA2652612A1 (es)
CL (1) CL2007001752A1 (es)
DE (1) DE602007004333D1 (es)
DK (1) DK2035385T3 (es)
DO (1) DOP2008000053A (es)
EA (1) EA015712B1 (es)
EC (1) ECSP088992A (es)
ES (1) ES2336630T3 (es)
HR (1) HRP20100147T1 (es)
IL (1) IL195005A0 (es)
MA (1) MA30757B1 (es)
MX (1) MX2008015904A (es)
NO (1) NO20090289L (es)
PE (1) PE20080338A1 (es)
PL (1) PL2035385T3 (es)
PT (1) PT2035385E (es)
SI (1) SI2035385T1 (es)
TN (1) TNSN08529A1 (es)
TW (1) TW200812970A (es)
WO (1) WO2007149730A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
MX2015010937A (es) 2013-03-15 2015-10-29 Ampio Pharmaceuticals Inc Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas.
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
RU2020136589A (ru) 2014-08-18 2020-12-24 Ампио Фармасьютикалз, Инк. Лечение дегенеративных заболеваний суставов
WO2016201605A1 (zh) * 2015-06-15 2016-12-22 廖勇 一种治疗乙型肝炎病毒的靶点
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CA3186565A1 (en) * 2020-07-22 2022-01-27 Lei Miao Unit dosage composition of akt inhibitor
CN115843298B (zh) * 2020-07-22 2024-03-29 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
CN1768040A (zh) * 2003-03-28 2006-05-03 伊莱利利公司 作为akt(蛋白激酶b)抑制剂的异喹啉－5－磺酸酰胺
GB0317315D0 (en) 2003-07-24 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
WO2005054202A1 (en) * 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)

Also Published As

Publication number Publication date
DE602007004333D1 (de) 2010-03-04
DOP2008000053A (es) 2009-01-15
US7998977B2 (en) 2011-08-16
SI2035385T1 (sl) 2010-05-31
KR101067551B1 (ko) 2011-09-27
NO20090289L (no) 2009-01-19
EP2035385A2 (en) 2009-03-18
WO2007149730A3 (en) 2008-04-24
PL2035385T3 (pl) 2010-06-30
KR20090015978A (ko) 2009-02-12
AR061240A1 (es) 2008-08-13
US20090221633A1 (en) 2009-09-03
WO2007149730A2 (en) 2007-12-27
AU2007261120A1 (en) 2007-12-27
ECSP088992A (es) 2009-01-30
MX2008015904A (es) 2009-01-12
ES2336630T3 (es) 2010-04-14
CA2652612A1 (en) 2007-12-27
CL2007001752A1 (es) 2008-01-18
DK2035385T3 (da) 2010-03-22
BRPI0713136A2 (pt) 2012-04-17
JP2009541335A (ja) 2009-11-26
IL195005A0 (en) 2009-08-03
ATE455102T1 (de) 2010-01-15
HRP20100147T1 (hr) 2010-04-30
EP2035385B1 (en) 2010-01-13
EA200970041A1 (ru) 2009-06-30
EA015712B1 (ru) 2011-10-31
MA30757B1 (fr) 2009-10-01
TNSN08529A1 (en) 2010-04-14
PT2035385E (pt) 2010-03-01
TW200812970A (en) 2008-03-16

Similar Documents

Publication Publication Date Title
PE20080338A1 (es) 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)
NO20090878L (no) Smac peptidoetterligninger nyttige som IAP-inhibitorer
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
PA8852901A1 (es) Inhibidores de proteina cinasa
CL2011002761A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores del canal romk; composición farmacéutica; y su uso para provocar diuresis, natriuresis o ambas, hipertension, insuficiencia cardiaca, insuficiencia renal aguda y crónica y síndrome nefrótico, entre otras enfermedades.
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
HN2011001446A (es) Compuesto utiles para inhibir chk1
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
EA200801978A1 (ru) Способ получения и применения фармакологически активного n-карбамоилметил-4(r)-фенил-2-пирролидинона
PE20151055A1 (es) Compuestos triciclicos para inhibir el canal cftr
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
ATE509958T1 (de) Gegen cathepsin s gerichtete therapie

Legal Events

Date Code Title Description
FC Refusal